Literature DB >> 11081807

Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients.

M Schwaninger1, P Ringleb, A Annecke, R Winter, B Kohl, E Werle, W Fiehn, P A Rieser, I Walter-Sack.   

Abstract

Lipoprotein(a) [Lp(a)] has been identified as an independent risk factor for vascular diseases. There are no data on Lp(a) levels in patients on long-term medication with carbamazepine, phenytoin, phenobarbital, or valproate. To investigate the effects of such treatment on Lp(a) levels and common carotid artery intima media thickness we studied 51 epileptic outpatients on long-term antiepileptic medication and 51 age-and sex-matched controls. Lp(a) levels above 45 mg/dl were found in 11 of 50 patients, but in only 4 of 51 controls (P < 0.05). The mean serum concentration of Lp(a) was 33.0+/-7.0 mg/dl in patients and 16.9+/-2.7 mg/dl in controls (P < 0.05). Epileptic patients also had a thicker intima media of the common carotid artery (0.79+/-0.04 mm) than controls (0.69+/-0.02 mm, P < 0.05) as measured by B-mode ultrasonography. Our results suggest an untoward effect of long-term antiepileptic medication on Lp(a) serum concentrations. Elevated Lp(a) levels might be a risk factor for arteriosclerosis in epileptic patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11081807     DOI: 10.1007/s004150070111

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  10 in total

1.  Impact of age on cerebrovascular dilation versus reactivity to hypercapnia.

Authors:  Nicole S Coverdale; Mark B Badrov; J Kevin Shoemaker
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-12       Impact factor: 6.200

Review 2.  Growing old with epilepsy: the neglected issue of cognitive and brain health in aging and elder persons with chronic epilepsy.

Authors:  Bruce Hermann; Michael Seidenberg; Mark Sager; Cynthia Carlsson; Barry Gidal; Raj Sheth; Paul Rutecki; Sanjay Asthana
Journal:  Epilepsia       Date:  2007-11-21       Impact factor: 5.864

3.  Plaques on the wall: inducing anticonvulsant use and atherogenesis.

Authors:  Scott Mintzer
Journal:  Epilepsy Curr       Date:  2012-11       Impact factor: 7.500

4.  Antiepileptic drugs and markers of vascular risk.

Authors:  Carla Lopinto-Khoury; Scott Mintzer
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

5.  Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women.

Authors:  Pilar Orozco
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

6.  Altered lipid metabolism in post-traumatic epileptic rat model: one proposed pathway.

Authors:  Niraj Kumar Srivastava; Somnath Mukherjee; Rajkumar Sharma; Jharana Das; Rohan Sharma; Vikas Kumar; Neeraj Sinha; Deepak Sharma
Journal:  Mol Biol Rep       Date:  2019-01-31       Impact factor: 2.316

7.  Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings.

Authors:  Elisabetta Patorno; Robert J Glynn; Sonia Hernandez-Diaz; Jerry Avorn; Peter M Wahl; Rhonda L Bohn; Daniel Mines; Jun Liu; Sebastian Schneeweiss
Journal:  J Am Heart Assoc       Date:  2013-07-30       Impact factor: 5.501

Review 8.  Cognition and dementia in older patients with epilepsy.

Authors:  Arjune Sen; Valentina Capelli; Masud Husain
Journal:  Brain       Date:  2018-06-01       Impact factor: 13.501

9.  Role of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial.

Authors:  Toktam Faghihi; Adel Jahed; Javad Mahmoudi-Gharaei; Vandad Sharifi; Shahin Akhondzadeh; Padideh Ghaeli
Journal:  Daru       Date:  2012-10-04       Impact factor: 3.117

10.  Effects of Antiepileptic Drugs on the Carotid Artery Intima-Media Thickness in Epileptic Patients.

Authors:  Qilun Lai; Chunhong Shen; Yang Zheng; Yinxi Zhang; Yi Guo; Meiping Ding
Journal:  J Clin Neurol       Date:  2017-09-04       Impact factor: 3.077

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.